Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06431373 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Study acronym: CLARITY
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 12, 2026 (before its estimated September 11, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruitingv7 Show 4 more changesShow less
    • Enrollment target: estimated 300 to confirmed 371
    • Study sites: 40 to 107
    • Eligibility criteria revised
    • Secondary endpoints revised (5)
  2. Study sites: 20 to 40v6
  3. Trial status: Not Yet Recruiting to Recruitingv5 Show 8 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 220 to 300
    • Study sites: 1 to 20
    • Primary completion date: Aug 23, 2026 to Sep 11, 2026
    • Study completion date: Aug 23, 2027 to Feb 1, 2028
    • Start date changed from estimate of Aug 23, 2024 to Sep 11, 2024
    • Secondary endpoints: 3 to 5
    • Eligibility criteria expanded, about 2 words
  4. Study Status, Contacts/Locationsv4
  5. Interventions: Brepocitinib 45 mg PO QD (Drug), Placebo PO QD (Drug) to Brepocitinib PO QD (Drug), Placebo PO QD (Drug)
    • Eligibility criteria shortened, about 50 words
    • Study title shortened, about 1 word
    v3
  6. Eligibility criteria shortened, about 3 words
    • Study title shortened, about 2 words
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Trial Details
NCT Number NCT06431373
Lead Sponsor Priovant Therapeutics, Inc.
Conditions
(from sponsor)		 Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Related terms Uveitis, Uveitis, Intermediate, Uveitis, Posterior
Enrollment 371 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov